Literature DB >> 15595433

Defensins: natural anti-HIV peptides.

Theresa L Chang1, Mary E Klotman.   

Abstract

Mammalian defensins are small cationic antimicrobial peptides predominantly found in leukocytes and epithelial cells engaged in host defense. These peptides act as effector molecules in innate immunity as well as regulators in adaptive immunity. Increasing evidence indicates that defensins are effective inhibitors of HIV-1. While the level of defensins in HIV-1 infected individuals has not been determined, neutropenia and neutrophil dysfunction associated with HIV disease progression may result in altered alpha-defensin production. This review provides an overview of the structure and function of defensins, and focuses on the anti-HIV-1 activity of defensins and the mechanism of this activity. Although many questions remain, studying the complex function of defensins in innate immunity against HIV has implications for our further understanding of disease progression and for the development of novel approaches to prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15595433

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  26 in total

Review 1.  Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects.

Authors:  Gary A Jarvis; Theresa L Chang
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

2.  Amniotic fluid exhibits an innate inhibitory activity against HIV type 1 replication in vitro.

Authors:  Azadeh Farzin; Pamela Boyer; Bonnie Ank; Karin Nielsen-Saines; Yvonne Bryson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-07       Impact factor: 2.205

3.  [Antimicrobial peptides. A perspective for the treatment of chronic wounds?].

Authors:  A Körber; S Grabbe; J Dissemond
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

4.  Comprehensive defensin assay for saliva.

Authors:  Michael S Gardner; Megan D Rowland; Amy Y Siu; Jonathan L Bundy; Diane K Wagener; James L Stephenson
Journal:  Anal Chem       Date:  2009-01-15       Impact factor: 6.986

5.  Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.

Authors:  Marta Rodríguez-García; Núria Climent; Harold Oliva; Víctor Casanova; Rafael Franco; Agathe Leon; José M Gatell; Felipe García; Teresa Gallart
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 6.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

7.  Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission.

Authors:  Mary E Klotman; Aprille Rapista; Natalia Teleshova; Amanda Micsenyi; Gary A Jarvis; Wuyuan Lu; Edith Porter; Theresa L Chang
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.

Authors:  R Alvarez; J Reading; D F L King; M Hayes; P Easterbrook; F Farzaneh; S Ressler; F Yang; D Rowley; A Vyakarnam
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites.

Authors:  Aiping Wang; Fang Chen; Yingjie Wang; Mingqiang Shen; Yang Xu; Jian Hu; Song Wang; Fang Geng; Cheng Wang; Xinze Ran; Yongping Su; Tianmin Cheng; Junping Wang
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

10.  Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

Authors:  Marc C Levesque; M Anthony Moody; Kwan-Ki Hwang; Dawn J Marshall; John F Whitesides; Joshua D Amos; Thaddeus C Gurley; Sallie Allgood; Benjamin B Haynes; Nathan A Vandergrift; Steven Plonk; Daniel C Parker; Myron S Cohen; Georgia D Tomaras; Paul A Goepfert; George M Shaw; Jörn E Schmitz; Joseph J Eron; Nicholas J Shaheen; Charles B Hicks; Hua-Xin Liao; Martin Markowitz; Garnett Kelsoe; David M Margolis; Barton F Haynes
Journal:  PLoS Med       Date:  2009-07-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.